Skip to content

Study · Animal study (in vivo) · mouse · 2021

5 results

Nicotinamide Mononucleotide Prevents Free Fatty Acid-Induced Reduction in Glucose Tolerance by Decreasing Insulin Clearance.

Nahle A, Joseph YD, Pereira S, Mori Y, Poon F, Ghadieh HE, Ivovic A, Desai T, Ghanem SS, Asalla S, Muturi HT, Jentz EM, Joseph JW, Najjar SM, Giacca A

International journal of molecular sciences8 Dec 2021Cited by 11 (Europe PMC)

PMID34948019 (opens in a new tab)PMCIDPMC8709165 (opens in a new tab)DOI10.3390/ijms222413224 (opens in a new tab)PepBankPUB-34948019
Download PDFPubMedAsk about this study
Jump to 5 results

Summary

The NAD-dependent deacetylase SIRT1 improves β cell function. Accordingly, nicotinamide mononucleotide (NMN), the product of the rate-limiting step in NAD synthesis, prevents β cell dysfunction and glucose intolerance in mice fed a high-fat diet. The current study was performed to assess the effects of NMN on β cell dysfunction and glucose intolerance that are caused specifically by increased circulating free fatty acids (FFAs). NMN was intravenously infused, with or without oleate, in C57BL/6J mice over a 48-h-period to elevate intracellular NAD levels and consequently increase SIRT1 activity. Administration of NMN in the context of elevated plasma FFA levels considerably improved glucose tolerance. This was due not only to partial protection from FFA-induced β cell dysfunction but also, unexpectedly, to a significant decrease in insulin clearance. However, in conditions of normal FFA levels, NMN impaired glucose tolerance due to decreased β cell function. The presence of this dual action of NMN suggests caution in its proposed therapeutic use in humans.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with elevated plasma free fatty acids, NMN considerably improved glucose tolerance.

    In plain wordsIn mice with elevated free fatty acids, NMN improved glucose tolerance.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseGlucose tolerance with elevated FFAs
    Study

    mousen: not reported in source

    C57BL/6J mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intravenous infusion · 48 hAs given in this study (mouse).

    Source sentences

    Summary
    Administration of NMN in the context of elevated plasma FFA levels considerably improved glucose tolerance.
    1 context sentence
    Summary · context
    NMN was intravenously infused, with or without oleate, in C57BL/6J mice over a 48-h-period to elevate intracellular NAD levels and consequently increase SIRT1 activity.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with elevated free fatty acids, NMN partially protected against fatty acid-induced beta-cell dysfunction.

    In plain wordsIn mice with elevated free fatty acids, NMN partially protected beta-cell function.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseBeta-cell dysfunction with elevated FFAs
    Study

    mousen: not reported in source

    C57BL/6J mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intravenous infusion · 48 hAs given in this study (mouse).

    Source sentences

    Summary
    This was due not only to partial protection from FFA-induced β cell dysfunction but also, unexpectedly, to a significant decrease in insulin clearance.
    2 context sentences
    Summary · context
    Administration of NMN in the context of elevated plasma FFA levels considerably improved glucose tolerance.
    Summary · context
    NMN was intravenously infused, with or without oleate, in C57BL/6J mice over a 48-h-period to elevate intracellular NAD levels and consequently increase SIRT1 activity.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with elevated free fatty acids, NMN significantly decreased insulin clearance.

    In plain wordsIn mice with elevated free fatty acids, NMN reduced insulin clearance.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseInsulin clearance
    Study

    mousen: not reported in source

    C57BL/6J mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intravenous infusion · 48 hAs given in this study (mouse).

    Source sentences

    Summary
    This was due not only to partial protection from FFA-induced β cell dysfunction but also, unexpectedly, to a significant decrease in insulin clearance.
    2 context sentences
    Summary · context
    Administration of NMN in the context of elevated plasma FFA levels considerably improved glucose tolerance.
    Summary · context
    NMN was intravenously infused, with or without oleate, in C57BL/6J mice over a 48-h-period to elevate intracellular NAD levels and consequently increase SIRT1 activity.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with normal free fatty acid levels, NMN impaired glucose tolerance.

    In plain wordsIn mice with normal free fatty acid levels, NMN impaired glucose tolerance.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseGlucose tolerance with normal FFAs
    Study

    mousen: not reported in source

    C57BL/6J mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intravenous infusion · 48 hAs given in this study (mouse).

    Source sentences

    Summary
    However, in conditions of normal FFA levels, NMN impaired glucose tolerance due to decreased β cell function.
    1 context sentence
    Summary · context
    NMN was intravenously infused, with or without oleate, in C57BL/6J mice over a 48-h-period to elevate intracellular NAD levels and consequently increase SIRT1 activity.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In mice with normal free fatty acid levels, NMN decreased beta-cell function.

    In plain wordsIn mice with normal free fatty acid levels, NMN reduced beta-cell function.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    DecreaseBeta-cell function with normal FFAs
    Study

    mousen: not reported in source

    C57BL/6J mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intravenous infusion · 48 hAs given in this study (mouse).

    Source sentences

    Summary
    However, in conditions of normal FFA levels, NMN impaired glucose tolerance due to decreased β cell function.
    1 context sentence
    Summary · context
    NMN was intravenously infused, with or without oleate, in C57BL/6J mice over a 48-h-period to elevate intracellular NAD levels and consequently increase SIRT1 activity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.